Top

Published in:

20-09-2023 | Cannabinoid

Δ⁹-Tetrahydrocannabinol Effects on Respiration and Heart Rate Across Route of Administration in Female and Male Mice

Authors: Lucas T. Laudermilk, Julie A. Marusich, Jenny L. Wiley

Published in: Cardiovascular Toxicology | Issue 11-12/2023

Abstract

The physiological impact of cannabinoid receptor agonists is of great public health interest due to their increased use in recreational and therapeutic contexts. However, the body of literature on cannabinoid receptor agonists includes multiple confounding variables that complicate comparisons across studies, including route of administration, timeline across which phenotypes are observed, agonist dose, and sex of the study cohort. In this study, we characterized the impact of sex and route of administration on Δ⁹-tetrahydrocannabinol (THC)-induced changes in cardiopulmonary phenotypes in mice. Using noninvasive plethysmography and telemetry, we monitored heart rate and respiration in the same cohort of animals across aerosol, oral gavage, subcutaneous, and intraperitoneal administrations of THC (0–30 mg/kg THC for oral gavage, subcutaneous, and intraperitoneal, and 0-300 mg/ml THC for aerosol). All routes of THC administration altered respiratory minute volume and heart rate, with the direction of effects typically being consistent across dependent measures. THC primarily decreased respiration and heart rate, but females given oral gavage THC showed increased heart rate. Intraperitoneal and subcutaneous THC produced the longest-lasting effects, including THC-induced alterations in physiological parameters for up to 10 h, whereas effects of aerosolized THC were short lived. The fastest onset of effects of THC occurred for aerosolized and intraperitoneal THC. Altogether, the work herein establishes the impact of dosing route on THC-induced heart rate and respiratory alteration in male and female mice. This study highlights important differences in the timeline of cardiopulmonary response to THC following the most common preclinical routes of administration.

Available only for authorised users

Hasin, D. S., Shmulewitz, D., & Sarvet, A. L. (2019). Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: A narrative review and new findings. American Journal of Drug and Alcohol Abuse, 45, 623–643. https://doi.org/10.1080/00952990.2019.1569668.CrossRefPubMed

ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in cannabis potency over the last 2 fecades (1995–2014): Analysis of current data in the United States. Biological Psychiatry, 79, 613–619. https://doi.org/10.1016/j.biopsych.2016.01.004.CrossRefPubMedPubMedCentral

Cinnamon Bidwell, L., YorkWilliams, S. L., Mueller, R. L., Bryan, A. D., & Hutchison, K. E. (2018). Exploring cannabis concentrates on the legal market: User profiles, product strength, and health-related outcomes. Addictive Behaviors Reports, 8, 102–106. https://doi.org/10.1016/j.abrep.2018.08.004CrossRefPubMedPubMedCentral

Smart, R., Caulkins, J. P., Kilmer, B., Davenport, S., & Midgette, G. (2017). Variation in cannabis potency and prices in a newly legal market: Evidence from 30 million cannabis sales in Washington state. Addiction, 112, 2167–2177. https://doi.org/10.1111/add.13886.CrossRefPubMedPubMedCentral

Mehmedic, Z., Chandra, S., Slade, D., Denham, H., Foster, S., Patel, A. S., Ross, S. A., Khan, I. A., & ElSohly, M. A. (2010). Potency trends of ∆9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. Journal of Forensic Sciences, 55, 1209–1217. https://doi.org/10.1111/j.1556-4029.2010.01441.x.CrossRefPubMed

Modaresi, F., & Talachian, K. (2022). The characteristics of clinical trials on cannabis and cannabinoids: A review of trials for therapeutic or drug development purposes. Pharmaceutical Medicine, 36, 387–400. https://doi.org/10.1007/s40290-022-00447-7CrossRefPubMed

Vandrey, R., Herrmann, E. S., Mitchell, J. M., Bigelow, G. E., Flegel, R., LoDico, C., & Cone, E. J. (2017). Pharmacokinetic Profile of oral Cannabis in humans: Blood and oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. Journal of Analytical Toxicology, 41, 83–99. https://doi.org/10.1093/jat/bkx012.CrossRefPubMedPubMedCentral

Naef, M., Russmann, S., Petersen-Felix, S., & Brenneisen, R. (2004). Development and pharmacokinetic characterization of pulmonal and intravenous Δ-9-tetrahydrocannabinol (THC) in humans. Journal of Pharmaceutical Sciences, 93, 1176–1184. https://doi.org/10.1002/jps.20037.CrossRefPubMed

Spindle, T. R., Cone, E. J., Goffi, E., Weerts, E. M., Mitchell, J. M., Winecker, R. E., Bigelow, G. E., Flegel, R. R., & Vandrey, R. (2020). Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2020.107937CrossRefPubMedPubMedCentral

10.

Sholler, D. J., Zamarripa, C. A., Spindle, T. R., Martin, E. L., Kuntz, D., Vandrey, R., & Grabenauer, M. (2022). Urinary excretion profile of cannabinoid analytes following acute administration of oral and vaporized cannabis in infrequent cannabis users. Journal of Analytical Toxicology, 46, 882–890. https://doi.org/10.1093/jat/bkac042CrossRefPubMedPubMedCentral

11.

Huestis, M. A., Blount, B. C., Milan, D. F., Newmeyer, M. N., Schroeder, J., & Smith, M. L. (2019). Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. Drug Testing and Analysis, 11, 968–975. https://doi.org/10.1002/dta.2576.CrossRefPubMed

12.

Rabgay, K., Waranuch, N., Chaiyakunapruk, N., Sawangjit, R., Ingkaninan, K., & Dilokthornsakul, P. (2020). The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis. Journal of the American Pharmacists Association, 60, 225–234. https://doi.org/10.1016/j.japh.2019.07.015CrossRefPubMed

13.

Swortwood, M. J., Newmeyer, M. N., Andersson, M., Abulseoud, O. A., Scheidweiler, K. B., & Huestis, M. A. (2017). Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Testing and Analysis, 9, 905–915. https://doi.org/10.1002/dta.2092.CrossRefPubMed

14.

Lemberger, L., Weiss, J. L., Watanabe, A. M., Galanter, I. M., Wyatt, R. J., & Cardon, P. V. (1972). Δ-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. New England Journal of Medicine, 286, 685–688. https://doi.org/10.1056/nejm197203302861303.CrossRefPubMed

15.

Sinclair, J., Collett, L., Abbott, J., Pate, D. W., Sarris, J., & Armour, M. (2021). Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms. PLoS One, 16, e0258940. https://doi.org/10.1371/journal.pone.0258940.CrossRefPubMedPubMedCentral

16.

Wiley, J. L., Taylor, S. I., & Marusich, J. A. (2021). ∆(9)-Tetrahydrocannabinol discrimination: Effects of route of administration in rats. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2021.108827CrossRefPubMedPubMedCentral

17.

Hložek, T., Uttl, L., Kadeřábek, L., Balíková, M., Lhotková, E., Horsley, R. R., Nováková, P., Šíchová, K., Štefková, K., Tylš, F., Kuchař, M., & Páleníček, T. (2017). Pharmacokinetic and behavioural profile of THC, CBD, and THC + CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. European Neuropsychopharmacology, 27, 1223–1237. https://doi.org/10.1016/j.euroneuro.2017.10.037.CrossRefPubMed

18.

Marshell, R., Kearney-Ramos, T., Brents, L. K., Hyatt, W. S., Tai, S., Prather, P. L., & Fantegrossi, W. E. (2014). In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid ∆9-THC in mice: Inhalation versus intraperitoneal injection. Pharmacology, Biochemistry and Behavior, 124, 40–47.CrossRefPubMed

19.

Baglot, S. L., Hume, C., Petrie, G. N., Aukema, R. J., Lightfoot, S. H. M., Grace, L. M., Zhou, R., Parker, L., Rho, J. M., Borgland, S. L., McLaughlin, R. J., Brechenmacher, L., & Hill, M. N. (2021). Pharmacokinetics and central accumulation of Δ-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats. Scientific Reports. https://doi.org/10.1038/s41598-021-03242-7CrossRefPubMedPubMedCentral

20.

Welch, S. P., Thomas, C., & Patrick, G. S. (1995). Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. Journal of Pharmacology and Experimental Therapeutics, 272, 310–321.PubMed

21.

Borgen, L. A., & Davis, W. M. (1973). Vehicle and route of administration as parameters affecting operant behavioral effects of 9 -tetrahydrocannabinol. Journal of Pharmaceutical Sciences, 62, 479–480. https://doi.org/10.1002/jps.2600620327.CrossRefPubMed

22.

Manwell, L. A., Ford, B., Matthews, B. A., Heipel, H., & Mallet, P. E. (2014). A vapourized ∆(9)-tetrahydrocannabinol (∆(9)-THC) delivery system part II: Comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents. Journal of Pharmacological and Toxicological Methods, 70, 112–119. https://doi.org/10.1016/j.vascn.2014.06.004.CrossRefPubMed

23.

Lichtman, A. H., Dimen, K. R., & Martin, B. R. (1995). Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology, 119, 282–290. https://doi.org/10.1007/bf02246292CrossRefPubMed

24.

Lucas, C. J., Galettis, P., & Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology, 84, 2477–2482. https://doi.org/10.1111/bcp.13710.CrossRefPubMedPubMedCentral

25.

Spindle, T. R., Martin, E. L., Grabenauer, M., Woodward, T., Milburn, M. A., & Vandrey, R. (2021). Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. Journal of Psychopharmacology (Oxford England), 35, 786–803. https://doi.org/10.1177/02698811211021583.CrossRefPubMed

26.

Spindle, T. R., Cone, E. J., Herrmann, E. S., Mitchell, J. M., Flegel, R., LoDico, C., Bigelow, G. E., & Vandrey, R. (2020). Pharmacokinetics of cannabis brownies: A controlled examination of ∆9-tetrahydrocannabinol and metabolites in blood and oral fluid of healthy adult males and females. Journal of Analytical Toxicology, 44, 661–671. https://doi.org/10.1093/jat/bkaa067CrossRefPubMedPubMedCentral

27.

Sholler, D. J., Strickland, J. C., Spindle, T. R., Weerts, E. M., & Vandrey, R. (2021). Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addiction Biology, 26, e12968. https://doi.org/10.1111/adb.12968CrossRefPubMed

28.

Samudre, S. S., Schneider, J. L., Oltmanns, M. H., Hosseini, A., Pratap, K., Loose-Thurman, P., Allen, R. C., Williams, P. B., Lattanzio, F. A. Jr., & Sheppard, J. D. Jr. (2008). Comparison of topical and intravenous administration of WIN 55-212-2 in normotensive rabbits. Current Eye Research, 33, 857–863. https://doi.org/10.1080/02713680802419724.CrossRefPubMed

29.

Chaperon, F., Soubrié, P., Puech, A. J., & Thiébot, M. H. (1998). Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology, 135, 324–332. https://doi.org/10.1007/s002130050518CrossRefPubMed

30.

Gardner, E. L., Paredes, W., Smith, D., Donner, A., Milling, C., Cohen, D., & Morrison, D. (1988). Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology, 96, 142–144. https://doi.org/10.1007/bf02431546CrossRefPubMed

31.

Lefever, T. W., Marusich, J. A., Antonazzo, K. R., & Wiley, J. L. (2014). Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model. Pharmacology, Biochemistry and Behavior, 118, 30–35. https://doi.org/10.1016/j.pbb.2014.01.002.CrossRefPubMed

32.

Valjent, E., & Maldonado, R. (2000). A behavioural model to reveal place preference to Δ 9-tetrahydrocannabinol in mice. Psychopharmacology, 147, 436–438. https://doi.org/10.1007/s002130050013CrossRefPubMed

33.

Vlachou, S., Nomikos, G. G., Stephens, D. N., & Panagis, G. (2007). Lack of evidence for appetitive effects of Δ9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents. Behavioural Pharmacology, 18, 311–319. https://doi.org/10.1097/FBP.0b013e3282186cf2CrossRefPubMed

34.

Balster, R. L., & Prescott, W. R. (1992). Δ 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neuroscience and Biobehavioral Reviews, 16, 55–62.CrossRefPubMed

35.

Wiley, J. L., Lowe, J. A., Balster, R. L., & Martin, B. R. (1995). Antagonism of the discriminative stimulus effects of Δ 9-tetrahydrocannabinol in rats and rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 275, 1–6.PubMed

36.

Aceto, M. D., Scates, S. M., Lowe, J. A., & Martin, B. R. (1996). Dependence on Δ 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. Journal of Pharmacology and Experimental Therapeutics, 278, 1290–1295.PubMed

37.

Lichtman, A. H., Fisher, J., & Martin, B. R. (2001). Precipitated cannabinoid withdrawal is reversed by Δ(9)-tetrahydrocannabinol or clonidine. Pharmacology, Biochemistry and Behavior, 69, 181–188. https://doi.org/10.1016/s0091-3057(01)00514-7CrossRefPubMed

38.

Trexler, K. R., Eckard, M. L., & Kinsey, S. G. (2019). CB(1) positive allosteric modulation attenuates ∆(9)-THC withdrawal and NSAID-induced gastric inflammation. Pharmacology, Biochemistry and Behavior, 177, 27–33. https://doi.org/10.1016/j.pbb.2018.12.009.CrossRefPubMed

39.

Tsou, K., Patrick, S. L., & Walker, J. M. (1995). Physical withdrawal in rats tolerant to Δ 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. European Journal of Pharmacology, 280(15), R13. https://doi.org/10.1016/0014-2999(95)00360-w.CrossRefPubMed

40.

Delaunois, A., Dedoncker, P., Hanon, E., & Guyaux, M. (2009). Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat. Journal of Pharmacological and Toxicological Methods, 60, 117–129. https://doi.org/10.1016/j.vascn.2009.07.003.CrossRefPubMed

41.

National Research Council. (2011). Guide for the care and use of laboratory animals National. Academies Press.

42.

Wiley, J. L., Lefever, T. W., Glass, M., & Thomas, B. F. (2019). Do you feel it now? Route of administration and Δ(9)-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice. Neurotoxicology, 73, 161–167. https://doi.org/10.1016/j.neuro.2019.04.002CrossRefPubMedPubMedCentral

43.

Kitdumrongthum, S., & Trachootham, D. (2023). An individuality of response to cannabinoids: challenges in safety and efficacy of cannabis products. Molecules. https://doi.org/10.3390/molecules28062791CrossRefPubMedPubMedCentral

44.

Wiese, B. M., Alvarez Reyes, A., Vanderah, T. W., & Largent-Milnes, T. M. (2023). The endocannabinoid system and breathing. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2023.1126004CrossRefPubMedPubMedCentral

45.

Glass, M., Dragunow, M., & Faull, R. L. (1997). Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77, 299–318. https://doi.org/10.1016/s0306-4522(96)00428-9.CrossRefPubMed

46.

Wiese, B. M., Liktor-Busa, E., Levine, A., Couture, S. A., Nikas, S. P., Ji, L., Liu, Y., Mackie, K., Makriyannis, A., Largent-Milnes, T. M., & Vanderah, T. W. (2021). Cannabinoid-2 agonism with AM2301 mitigates morphine-induced respiratory depression. Cannabis and Cannabinoid Research, 6, 401–412. https://doi.org/10.1089/can.2020.0076CrossRefPubMedPubMedCentral

47.

Del Negro, C. A., Funk, G. D., & Feldman, J. L. (2018). Breathing matters. Nature Reviews Neuroscience, 19, 351–367. https://doi.org/10.1038/s41583-018-0003-6.CrossRefPubMedPubMedCentral

48.

Calignano, A., Kátona, I., Désarnaud, F., Giuffrida, A., La Rana, G., Mackie, K., Freund, T. F., & Piomelli, D. (2000). Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature, 408, 96–101. https://doi.org/10.1038/35040576.CrossRefPubMed

49.

Bozkurt, T. E. (2019). Endocannabinoid System in the Airways. Molecules. https://doi.org/10.3390/molecules24244626CrossRefPubMedPubMedCentral

50.

Tetrault, J. M., Crothers, K., Moore, B. A., Mehra, R., Concato, J., & Fiellin, D. A. (2007). Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Archives of Internal Medicine, 167, 221–228. https://doi.org/10.1001/archinte.167.3.221.CrossRefPubMedPubMedCentral

51.

Zwillich, C. W., Doekel, R., Hammill, S., & Weil, J. V. (1978). The effects of smoked marijuana on metabolism and respiratory control. The American Review of Respiratory Disease, 118, 885–891. https://doi.org/10.1164/arrd.1978.118.5.885.CrossRefPubMed

52.

Alon, M. H., & Saint-Fleur, M. O. (2017). Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respiratory Medicine Case Reports, 22, 137–141. https://doi.org/10.1016/j.rmcr.2017.07.011CrossRefPubMedPubMedCentral

53.

Jinwala, F. N., & Gupta, M. (2012). Synthetic cannabis and respiratory depression. Journal of Child and Adolescent Psychopharmacology, 22, 459–462. https://doi.org/10.1089/cap.2011.0122.CrossRefPubMed

54.

Wong, K. U., & Baum, C. R. (2019). Acute cannabis toxicity. Pediatric Emergency Care, 35, 799–804. https://doi.org/10.1097/pec.0000000000001970CrossRefPubMed

55.

Jones, R. T. (2002). Cardiovascular system effects of marijuana. The Journal of Clinical Pharmacology, 42, 58s–63s. https://doi.org/10.1002/j.1552-4604.2002.tb06004.xCrossRefPubMed

56.

Malit, L. A., Johnstone, R. E., Bourke, D. I., Kulp, R. A., Klein, V., & Smith, T. C. (1975). Intravenous Δ9-tetrahydrocannabinol: Effects of ventilatory control and cardiovascular dynamics. Anesthesiology, 42, 666–673.CrossRefPubMed

57.

DeFilippis, E. M., Bajaj, N. S., Singh, A., Malloy, R., Givertz, M. M., Blankstein, R., Bhatt, D. L., & Vaduganathan, M. (2020). Marijuana use in patients with cardiovascular disease: JACC review topic of the week. Journal of the American College of Cardiology, 75, 320–332. https://doi.org/10.1016/j.jacc.2019.11.025CrossRefPubMedPubMedCentral

58.

Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018). Cardiovascular effects of marijuana and synthetic cannabinoids: The good, the bad, and the ugly. Nature Reviews. Cardiology, 15, 151–166. https://doi.org/10.1038/nrcardio.2017.130.CrossRefPubMed

59.

Rezkalla, S., & Kloner, R. A. (2019). Cardiovascular effects of marijuana. Trends in Cardiovascular Medicine, 29, 403–407. https://doi.org/10.1016/j.tcm.2018.11.004.CrossRefPubMed

60.

Page, R. L., II., Allen, L. A., Kloner, R. A., Carriker, C. R., Martel, C., Morris, A. A., Piano, M. R., Rana, J. S., & Saucedo, J. F. (2020). Medical marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the american heart association. Circulation, 142, e131–e152. https://doi.org/10.1161/cir.0000000000000883CrossRefPubMed

61.

Farra, Y. M., Eden, M. J., Coleman, J. R., Kulkarni, P., Ferris, C. F., Oakes, J. M., & Bellini, C. (2020). Acute neuroradiological, behavioral, and physiological effects of nose-only exposure to vaporized cannabis in C57BL/6 mice. Inhal Toxicol, 32, 200–217. https://doi.org/10.1080/08958378.2020.1767237.CrossRefPubMed

62.

Iring, A., Ruisanchez, É., Leszl-Ishiguro, M., Horváth, B., Benkő, R., Lacza, Z., Járai, Z., Sándor, P., Di Marzo, V., Pacher, P., & Benyó, Z. (2013). Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One, 8, e53390. https://doi.org/10.1371/journal.pone.0053390.CrossRefPubMedPubMedCentral

63.

Schmid, K., Niederhoffer, N., & Szabo, B. (2003). Analysis of the respiratory effects of cannabinoids in rats. Naunyn-Schmiedeberg’S Archives of Pharmacology, 368, 301–308. https://doi.org/10.1007/s00210-003-0787-3.CrossRefPubMed

64.

Padley, J. R., Li, Q., Pilowsky, P. M., & Goodchild, A. K. (2003). Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats. British Journal of Pharmacology, 140, 384–394. https://doi.org/10.1038/sj.bjp.0705422.CrossRefPubMedPubMedCentral

65.

Pfitzer, T., Niederhoffer, N., & Szabo, B. (2004). Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats. British Journal of Pharmacology, 142, 943–952. https://doi.org/10.1038/sj.bjp.0705874.CrossRefPubMedPubMedCentral

66.

Vivian, J. A., Kishioka, S., Butelman, E. R., Broadbear, J., Lee, K. O., & Woods, J. H. (1998). Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A. Journal of Pharmacology and Experimental Therapeutics, 286, 697–703.PubMed

67.

Weed, P. F., Gerak, L. R., & France, C. P. (2018). Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys. European Journal of Pharmacology, 833, 94–99. https://doi.org/10.1016/j.ejphar.2018.05.041.CrossRefPubMedPubMedCentral

68.

Doherty, P. A., McCarthy, L. E., & Borison, H. L. (1983). Respiratory and cardiovascular depressant effects of nabilone, N-methyllevonantradol and Δ 9-tetrahydrocannabinol in anesthetized cats. Journal of Pharmacology and Experimental Therapeutics, 227, 508–516.PubMed

69.

Graham, J. D., & Li, D. M. (1973). Cardiovascular and respiratory effects of cannabis in cat and rat. British Journal of Pharmacology, 49, 1–10.CrossRefPubMedPubMedCentral

70.

Moss, I. R., & Friedman, E. (1976). Δ9-tetrahydrocannabinol: Depression of ventilatory regulation; other respiratory and cardiovascular effects. Life Sciences, 19, 99–104. https://doi.org/10.1016/0024-3205(76)90379-9.CrossRefPubMed

71.

Niederhoffer, N., & Szabo, B. (1999). Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. British Journal of Pharmacology, 126, 457–466. https://doi.org/10.1038/sj.bjp.0702337.CrossRefPubMedPubMedCentral

72.

Marchetti, B., Bilel, S., Tirri, M., Arfè, R., Corli, G., Roda, E., Locatelli, C. A., Cavarretta, E., De Giorgio, F., & Marti, M. (2023). The old and the new: Cardiovascular and respiratory alterations induced by acute JWH-018 administration compared to ∆(9)-THC-A preclinical study in mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021631CrossRefPubMedPubMedCentral

73.

Richards, J. R. (2020). Mechanisms for the risk of acute coronary syndrome and arrhythmia associated with phytogenic and synthetic cannabinoid use. Journal of Cardiovascular Pharmacology and Therapeutics, 25, 508–522. https://doi.org/10.1177/1074248420935743CrossRefPubMed

74.

Walker, M. K., Boberg, J. R., Walsh, M. T., Wolf, V., Trujillo, A., Duke, M. S., Palme, R., & Felton, L. A. (2012). A less stressful alternative to oral gavage for pharmacological and toxicological studies in mice. Toxicology and Applied Pharmacology, 260, 65–69. https://doi.org/10.1016/j.taap.2012.01.025CrossRefPubMedPubMedCentral

75.

Lunn, S., Diaz, P., O’Hearn, S., Cahill, S. P., Blake, A., Narine, K., & Dyck, J. R. B. (2019). Human pharmacokinetic parameters of orally administered ∆(9)-Tetrahydrocannabinol capsules are altered by Fed Versus fasted conditions and sex differences. Cannabis and Cannabinoid Research, 4, 255–264. https://doi.org/10.1089/can.2019.0037.CrossRefPubMedPubMedCentral

76.

Chaui-Berlinck, J. G., & Bicudo, J. E. (1998). The signal in total-body plethysmography: Errors due to adiabatic-isothermic difference. Respiration Physiology, 113, 259–270. https://doi.org/10.1016/S0034-5687(98)00060-7CrossRefPubMed

77.

Lundblad, L. K., Irvin, C. G., Adler, A., & Bates, J. H. (2002). A reevaluation of the validity of unrestrained plethysmography in mice. Journal of Applied Physiology, 93, 1198–1207. https://doi.org/10.1152/japplphysiol.00080.2002CrossRefPubMed

78.

Stucky, F., Cazzaniga, G., Aliverti, A., Kayser, B., & Uva, B. (2020). Automating the correction of flow integration drift during whole-body plethysmography. 2020 42nd Annual International Conference of the IEEE Engineering in Medicine & Biology Society, 2020, 5–8. https://doi.org/10.1109/embc44109.2020.9176170CrossRef

79.

Marusich, J. A., Gamage, T. F., Zhang, Y., Akinfiresoye, L. R., & Wiley, J. L. (2022). In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2022.173467CrossRefPubMed

Title: Δ9-Tetrahydrocannabinol Effects on Respiration and Heart Rate Across Route of Administration in Female and Male Mice
Authors: Lucas T. Laudermilk
Julie A. Marusich
Jenny L. Wiley
Publication date: 20-09-2023
Publisher: Springer US
Keyword: Cannabinoid
Published in: Cardiovascular Toxicology / Issue 11-12/2023
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-023-09810-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Δ⁹-Tetrahydrocannabinol Effects on Respiration and Heart Rate Across Route of Administration in Female and Male Mice

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11-12/2023

Development and Validation of a Nomogram Model for the Risk of Cardiac Death in Patients Treated with Chemotherapy for Esophageal Cancer

Systematical Evaluation of the Structure-Cardiotoxicity Relationship of 7-Azaindazole-based PI3K Inhibitors Designed by Bioisosteric Approach

Zinc Overload Induces Damage to H9c2 Cardiomyocyte Through Mitochondrial Dysfunction and ROS-Mediated Mitophagy

Salidroside Ameliorates Ischemia/Reperfusion-Induced Human Cardiomyocyte Injury by Inhibiting the Circ_0097682/miR-671-5p/USP46 Pathway

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page